Minnessotta Patent of the Month – October 2024
Rebiotix Inc. has pioneered a transformative approach to addressing gastrointestinal conditions through microbiota restoration therapy. Their invention centers on a meticulously prepared fecal microbiota suspension, blending advanced science with a natural solution to restore balance in the digestive tract. By combining fecal microbiota with a polyethylene glycol solution, the suspension achieves an optimal consistency and concentration of beneficial microbes, including over 1×10⁵ CFU of *Bacteroides* per milliliter.
This innovation begins with the collection of fecal samples from pre-screened donors, ensuring the highest safety and efficacy standards. These samples undergo rigorous processing, including dilution with a polyethylene glycol solution, which not only stabilizes the microbiota but also acts as a cryoprotectant during storage. Filtration further purifies the suspension, removing unwanted particulates while retaining its therapeutic potential.
A unique aspect of this invention lies in its adaptability for both storage and delivery. Encased in sealed sample bags, the microbiota suspension is frozen for long-term preservation, maintaining its viability until it reaches treatment facilities. This streamlined process—from donor screening to administration—ensures the therapy remains potent and practical for healthcare providers.
The fecal microbiota suspension represents a breakthrough in treating disorders like Clostridioides difficile infections and other imbalances of gut flora. By leveraging the natural diversity of a healthy microbiome, Rebiotix Inc.’s invention offers a targeted, minimally invasive treatment that addresses the root cause of gastrointestinal issues.
This cutting-edge solution bridges the gap between traditional and innovative medicine, emphasizing safety, efficiency, and transformative health benefits. It not only advances microbiome therapy but sets the stage for future innovations in digestive health. Rebiotix Inc. is reshaping the landscape of therapeutic options, empowering patients and clinicians with a scientifically grounded, life-changing tool.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.